These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 29087782)

  • 1. Vaccination in the immunotherapy of glioblastoma.
    Kong Z; Wang Y; Ma W
    Hum Vaccin Immunother; 2018 Feb; 14(2):255-268. PubMed ID: 29087782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
    Schaller TH; Sampson JH
    Expert Rev Vaccines; 2017 Jan; 16(1):27-36. PubMed ID: 27500911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine-based immunotherapy for glioblastoma.
    Thomas AA; Fisher JL; Ernstoff MS; Fadul CE
    CNS Oncol; 2013 Jul; 2(4):331-49. PubMed ID: 25054578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents.
    Tosti G; Cocorocchio E; Pennacchioli E; Ferrucci PF; Testori A; Martinoli C
    Expert Opin Biol Ther; 2014 Jul; 14(7):955-67. PubMed ID: 24670226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine strategies for glioblastoma: progress and future directions.
    Jackson C; Ruzevick J; Brem H; Lim M
    Immunotherapy; 2013 Feb; 5(2):155-67. PubMed ID: 23413907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of glioblastoma: Recent advances and future prospects.
    Yuan B; Wang G; Tang X; Tong A; Zhou L
    Hum Vaccin Immunother; 2022 Nov; 18(5):2055417. PubMed ID: 35344682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
    Batich KA; Swartz AM; Sampson JH
    Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in active-specific immunotherapy of brain malignancies.
    Tjoa BA; Salgaller ML
    Expert Opin Investig Drugs; 2000 Sep; 9(9):2093-101. PubMed ID: 11060795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives.
    Cuoco JA; Benko MJ; Busch CM; Rogers CM; Prickett JT; Marvin EA
    World Neurosurg; 2018 Dec; 120():302-315. PubMed ID: 30196171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.
    Heimberger AB; Sampson JH
    Expert Opin Biol Ther; 2009 Aug; 9(8):1087-98. PubMed ID: 19591631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives for immunotherapy in glioblastoma treatment.
    Finocchiaro G; Pellegatta S
    Curr Opin Oncol; 2014 Nov; 26(6):608-14. PubMed ID: 25210870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell immunotherapy for glioblastoma.
    Polyzoidis S; Ashkan K
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heat shock protein vaccines against glioblastoma: from bench to bedside.
    Ampie L; Choy W; Lamano JB; Fakurnejad S; Bloch O; Parsa AT
    J Neurooncol; 2015 Jul; 123(3):441-8. PubMed ID: 26093618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in human glioblastoma.
    Szabo AT; Carpentier AF
    Rev Neurol (Paris); 2011 Oct; 167(10):668-72. PubMed ID: 21885075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
    Erhart F; Buchroithner J; Reitermaier R; Fischhuber K; Klingenbrunner S; Sloma I; Hibsh D; Kozol R; Efroni S; Ricken G; Wöhrer A; Haberler C; Hainfellner J; Krumpl G; Felzmann T; Dohnal AM; Marosi C; Visus C
    Acta Neuropathol Commun; 2018 Dec; 6(1):135. PubMed ID: 30518425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DENDRITIC CELLS IN GLIOBLASTOMA TREATMENT: A MODERN VIEW OF THE PROBLEM AND OWN EXPERIENCE.
    Glavatskyi O; Khranovska N; Skachkova O; Gorbach O; Khmelnytskyi H; Shuba I; Pedachenko Y; Zemskova O; Zemskova O
    Exp Oncol; 2023 Dec; 45(3):282-296. PubMed ID: 38186026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.